Literature DB >> 24252043

Correlation between salivary epidermal growth factor levels and refractory intraoral manifestations in patients with Sjögren's syndrome.

Naoto Azuma1, Yoshinori Katada, Sachie Kitano, Masahiro Sekiguchi, Masayasu Kitano, Aki Nishioka, Naoaki Hashimoto, Kiyoshi Matsui, Tsuyoshi Iwasaki, Hajime Sano.   

Abstract

OBJECTIVE: To assess changes in salivary epidermal growth factor (EGF) levels and the correlation between these levels and the severity of intraoral manifestations in Sjögren's syndrome (SS).
METHODS: Forty SS patients and 23 controls were enrolled. Salivary EGF concentration was measured using an enzyme-linked immunosorbent assay, and intraoral manifestations were evaluated using a short version of the Oral Health Impact Profile (OHIP-14). The associations among salivary flow rate, EGF levels and the severity of intraoral manifestations were analyzed.
RESULTS: The total salivary EGF output was significantly decreased in the SS patients compared with the controls (9237.6 ± 8447.0 vs. 13296.9 ± 7907.1 pg/10 min, respectively, p = 0.033). In the SS patients, total EGF output and salivary flow rate showed a strong positive correlation (rs = 0.824, p = 0.0005), while total EGF output and disease duration showed a negative correlation (rs = -0.484, p = 0.008). Further, total EGF output was significantly correlated with the OHIP-14 score (rs = -0.721, p = 0.012).
CONCLUSIONS: The salivary flow rate and EGF levels are decreased in SS, and this deterioration in saliva quality causes refractory intraoral manifestations. Our findings have provided new therapeutic targets for SS.

Entities:  

Keywords:  Epidermal growth factor; Intraoral manifestation; Oral mucosal involvement; Saliva; Sjögren's syndrome

Mesh:

Substances:

Year:  2013        PMID: 24252043     DOI: 10.3109/14397595.2013.850766

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN: 1439-7595            Impact factor:   3.023


  7 in total

1.  The Role of Multisystem Disease in Composition of Autologous Serum tears and ocular surface symptom improvement.

Authors:  Madeline Ripa; Sayena Jabbehdari; Ghasem Yazdanpanah; Emoke Lukacs; Brandon Karcher; Omer Iqbal; Charles Bouchard
Journal:  Ocul Surf       Date:  2020-02-29       Impact factor: 5.033

Review 2.  Use of B lymphocyte stimulator inhibitor belimumab may be associated with a decrease in the serum concentration of epidermal growth factor in patients with primary Sjögren's syndrome.

Authors:  Sabeeda Kadavath; Slavica Bobic; Petros Efthimiou
Journal:  Clin Rheumatol       Date:  2015-02-05       Impact factor: 2.980

Review 3.  Deterioration in saliva quality in patients with Sjögren's syndrome: impact of decrease in salivary epidermal growth factor on the severity of intraoral manifestations.

Authors:  Naoto Azuma; Yoshinori Katada; Hajime Sano
Journal:  Inflamm Regen       Date:  2018-04-09

Review 4.  Oral-Health-Related Quality of Life in Adult Patients with Rheumatic Diseases-A Systematic Review.

Authors:  Gerhard Schmalz; Susann Patschan; Daniel Patschan; Dirk Ziebolz
Journal:  J Clin Med       Date:  2020-04-19       Impact factor: 4.241

5.  Fatigue in Sjögren's Syndrome: A Search for Biomarkers and Treatment Targets.

Authors:  Iris L A Bodewes; Peter J van der Spek; Leticia G Leon; Annemarie J M Wijkhuijs; Cornelia G van Helden-Meeuwsen; Liselotte Tas; Marco W J Schreurs; Paul L A van Daele; Peter D Katsikis; Marjan A Versnel
Journal:  Front Immunol       Date:  2019-02-26       Impact factor: 7.561

6.  Illness Experience and Quality of Life in Sjögren Syndrome Patients.

Authors:  Gonzalo Rojas-Alcayaga; Andrea Herrera; Iris Espinoza; Matías Rios-Erazo; Jacqueline Aguilar; Loreto Leiva; Nailah Shakhtur; Pamela Wurmann; Rinie Geenen
Journal:  Int J Environ Res Public Health       Date:  2022-09-02       Impact factor: 4.614

Review 7.  Modulation of Apoptosis by Cytotoxic Mediators and Cell-Survival Molecules in Sjögren's Syndrome.

Authors:  Hideki Nakamura; Yoshiro Horai; Toshimasa Shimizu; Atsushi Kawakami
Journal:  Int J Mol Sci       Date:  2018-08-11       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.